| Literature DB >> 34061757 |
Zhiyuan Hou1,2,3, Yixin Tong1, Fanxing Du1, Linyao Lu1, Sihong Zhao1, Kexin Yu1, Simon J Piatek4, Heidi J Larson4, Leesa Lin4,5.
Abstract
BACKGROUND: Monitoring public confidence and hesitancy is crucial for the COVID-19 vaccine rollout. Social media listening (infoveillance) can not only monitor public attitudes on COVID-19 vaccines but also assess the dissemination of and public engagement with these opinions.Entities:
Keywords: COVID-19; COVID-19 vaccine; acceptance; confidence; engagement; hesitancy; infodemiology; infoveillance; social media
Mesh:
Substances:
Year: 2021 PMID: 34061757 PMCID: PMC8202656 DOI: 10.2196/27632
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Flowchart of data process and analysis.
Figure 2Social media users’ attitudes toward COVID-19 vaccination.
Figure 3Expectations of COVID-19 vaccine R&D and introduction. R&D: research and development.
Confidence, complacency, and convenience related to COVID-19 vaccines on social media in 2020.
| Topics | New York, US | London, UK | Beijing, China | Mumbai, India | Sao Paulo, Brazil | |||||||||||||
|
| 3028 | 2672 | 4624 | 2166 | 396 | |||||||||||||
|
| Irrelevant posts | 1460 | 1232 | 1854 | 1126 | 182 | ||||||||||||
|
| Relevant posts | 1568 | 1440 | 2770 | 1040 | 214 | ||||||||||||
|
| ||||||||||||||||||
|
|
| |||||||||||||||||
|
|
|
| 115 (7.3) | 130 (9.0) | 712 (25.7) | 140 (13.5) | 22 (10.3) | |||||||||||
|
|
|
| Important | 96 (6.1) | 115 (8.0) | 651 (23.5) | 132 (12.7) | 22 (10.3) | ||||||||||
|
|
|
| Unimportant | 19 (1.2) | 16 (1.1) | 61 (2.2) | 8 (0.8) | 0 (0.0) | ||||||||||
|
|
|
| 217 (13.8) | 361 (25.1) | 928 (33.5) | 294 (28.3) | 71 (33.2) | |||||||||||
|
|
|
| Effective | 142 (9.1) | 305 (21.2) | 674 (24.3) | 261 (25.1) | 68 (31.8) | ||||||||||
|
|
|
| Ineffective | 75 (4.8) | 56 (3.9) | 254 (9.2) | 32 (3.1) | 3 (1.4) | ||||||||||
|
|
|
| 168 (10.7) | 354 (24.6) | 201 (7.3) | 190 (18.3) | 47 (22.0) | |||||||||||
|
|
|
| Safe | 35 (2.2) | 197 (13.7) | 143 (5.2) | 149 (14.3) | 43 (20.1) | ||||||||||
|
|
|
| Unsafe | 133 (8.5) | 157 (10.9) | 58 (2.1) | 41 (3.9) | 4 (1.9) | ||||||||||
|
|
|
| 294 (18.8) | 177 (12.3) | 148 (5.3) | 72 (6.9) | 8 (3.7) | |||||||||||
|
|
|
| Trust | 14 (0.9) | 19 (1.3) | 138 (5.0) | 16 (1.5) | 1 (0.5) | ||||||||||
|
|
|
| Distrust | 280 (17.9) | 158 (11.0) | 10 (0.4) | 56 (5.4) | 7 (3.3) | ||||||||||
|
|
|
| 90 (5.7) | 111 (7.7) | —c | 78 (7.5) | 2 (0.9) | |||||||||||
|
|
|
| Trust | 14 (0.9) | 44 (3.1) | — | 24 (2.3) | 2 (0.9) | ||||||||||
|
|
|
| Distrust | 76 (4.8) | 67 (4.7) | — | 54 (5.2) | 0 (0.0) | ||||||||||
|
|
| |||||||||||||||||
|
|
| Misinformation or rumors | 185 (11.8) | 158 (11.0) | 188 (6.8) | 30 (2.9) | 12 (5.6) | |||||||||||
|
|
| |||||||||||||||||
|
|
|
| 89 (5.7) | 52 (3.6) | 742 (26.8) | 45 (4.3) | 4 (1.9) | |||||||||||
|
|
|
| High | 80 (5.1) | 45 (3.1) | 688 (24.8) | 41 (3.9) | 4 (1.9) | ||||||||||
|
|
|
| Low | 9 (0.6) | 7 (0.5) | 54 (1.9) | 4 (0.4) | 0 (0.0) | ||||||||||
|
|
| |||||||||||||||||
|
|
| Vaccine accessibility | 94 (6.0) | 76 (5.3) | 283 (10.2) | 99 (9.5) | 49 (22.9) | |||||||||||
|
|
| Vaccine distribution | 309 (19.7) | 261 (18.1) | 325 (11.7) | 63 (6.1) | 26 (12.1) | |||||||||||
|
|
| Vaccine affordability | 107 (6.8) | 40 (2.8) | 197 (7.1) | 33 (3.2) | 20 (9.3) | |||||||||||
|
|
| 259 (16.5) | 470 (32.6) | 941 (34.0) | 270 (26.0) | 122 (57.0) | ||||||||||||
|
|
| AstraZeneca | 102 (6.5) | 388 (26.9) | 82 (3.0) | 218 (21.0) | 63 (29.4) | |||||||||||
|
|
| Moderna | 51 (3.3) | 30 (2.1) | 37 (1.3) | 31 (3.0) | 21 (9.8) | |||||||||||
|
|
| Pfizer | 88 (5.6) | 26 (1.8) | 34 (1.2) | 18 (1.7) | 27 (12.6) | |||||||||||
|
|
| Chinese vaccines | 25 (1.6) | 26 (1.8) | 831 (30.0) | 19 (1.8) | 13 (6.1) | |||||||||||
|
|
| 83 (5.3) | 51 (3.5) | 990 (35.7) | 34 (3.3) | 5 (2.3) | ||||||||||||
aWe assessed 50% random samples from New York and London due to the large sample size, and full samples in Beijing, Mumbai, and Sao Paulo.
bTopics are calculated among relevant posts.
cTrust in experts is not measured specifically for Sina Weibo posts from Beijing.
Followers and engagements of COVID-19 vaccine–related tweets in 2020.
| Topics | Followers, mean (SD) | Engagements, mean (SD) | ||||
|
| ||||||
|
|
| 3633.6 (12,614.4) | 6.1 (61.4) | |||
|
|
| Accept | 2448.8 (8614.6) | 7.9 (93.3) | ||
|
|
| Neutral | 4333.0 (16,250.7) | 5.8 (28.5) | ||
|
|
| Doubt | 4593.3 (18,245.7) | 10.0 (93.4) | ||
|
|
| Refuse | 2708.4 (12,504.3) | 6.4 (35.4) | ||
|
|
| 3011.0 (11,759.4) | 8.4 (94.4) | |||
|
|
| Positive | 2527.7 (9083.2) | 8.8 (104.3) | ||
|
|
| Neutral | 4449.8 (16,399.9) | 5.9 (31.9) | ||
|
|
| Negative | 3629.4 (14,833.2) | 8.2 (84.0) | ||
|
| ||||||
|
|
| 1763.6 (3727.9) | 3.6 (10.7) | |||
|
|
| Important | 1636.5 (3167.2) | 3.4 (9.9) | ||
|
|
| Unimportant | 2843.1 (6811.7) | 5.4 (16.5) | ||
|
|
| 3373.4 (13,960.7) | 10.9 (115.5) | |||
|
|
| Effective | 2505.6 (8366.8) | 10.6 (119.5) | ||
|
|
| Ineffective | 7430.1 (27,615.6) | 12.2 (94.7) | ||
|
|
| 3274.3 (14,058.0) | 13.1 (137.2) | |||
|
|
| Safe | 2086.2 (6191.7) | 10.3 (137.4) | ||
|
|
| Unsafe | 4778.0 (19,897.0) | 16.7 (137.1) | ||
|
|
| 3865.2 (16,363.8) | 9.7 (111.8) | |||
|
|
| Trust | 3055.6 (6573.5) | 52.8 (360.4) | ||
|
|
| Distrust | 3946.0 (17,036.6) | 5.4 (28.7) | ||
|
|
| 1887.9 (4812.1) | 3.8 (14.7) | |||
|
|
| Trust | 2029.1 (4076.9) | 3.0 (6.5) | ||
|
|
| Distrust | 1827.7 (5102.0) | 4.1 (17.1) | ||
|
| ||||||
|
| Misinformation or rumors | 3127.7 (11,610.5) | 14.0 (121.2) | |||
|
| ||||||
|
|
| 3017.9 (8282.9) | 5.4 (15.6) | |||
|
|
| High | 2909.7 (7848.9) | 5.1 (15.5) | ||
|
|
| Low | 3937.6 (11,554.1) | 8.1 (16.5) | ||
|
| ||||||
|
| Vaccine accessibility | 2351.5 (8915.4) | 2.6 (7.8) | |||
|
| Vaccine distribution | 3531.5 (12,541.6) | 5.8 (26.2) | |||
|
| Vaccine affordability | 2525.3 (4895.6) | 3.1 (8.3) | |||
aR&D: research and development.